Wissenschaftl. Titel | A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, parallel-group, double-blind, placebo-controlled, 16-week treatment period, and a follow-up/retreatment period |
Erkrankung |
Drüsen/Hormone/Stoffwechsel:
sonstige
Auge: sonstige |
weitere Prüfzentren | |
Kurzprotokoll | Kurzprotokoll |
Links | Zu den Ein- und Ausschlusskriterien |
erstellt 16.05.2022 Nicole Wamser
geändert 21.11.2024 Admin08